外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展

doi:10.16352/j.issn.1001-6325.2023.09.1457

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (9): 1457-1461.doi: 10.16352/j.issn.1001-6325.2023.09.1457

外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展

颜晨红¹, 金儿^2*

1.浙江中医药大学第四临床医学院,浙江杭州 310000;
2.浙江大学医学院附属杭州市第一人民医院呼吸内科, 浙江杭州 310000

收稿日期:2022-08-25 修回日期:2022-12-04 出版日期:2023-09-05 发布日期:2023-09-01
通讯作者: ^*amyier@163.com
基金资助:
杭州市科技计划引导项目(20201231Y023);浙江省基础公益研究计划(LY19H160031);浙江省医药卫生科技计划(2019KY126)

Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer

YAN Chenhong¹, JIN Er^2*

1. The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310000;
2. Department of Respiratory Medicine,Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China

Received:2022-08-25 Revised:2022-12-04 Online:2023-09-05 Published:2023-09-01
Contact: ^*amyier@163.com

摘要/Abstract

摘要： 外泌体PD-L1(exoPD-L1)可由非小细胞肺癌中癌细胞分泌,参与肿瘤的发生发展。外泌体PD-L1的检测具有无创、稳定等优点,可早期诊断非小细胞肺癌、判断肿瘤分期。外泌体PD-L1与肿瘤组织PD-L1相关,可用于筛选免疫治疗优势人群。动态监测外泌体PD-L1表达水平可评估肺癌患者免疫治疗效果。抑制外泌体PD-L1可辅助免疫治疗,为肺癌晚期患者的免疫治疗提供了较佳的临床价值。

关键词: 非小细胞肺癌, 外泌体, PD-L1, 诊断, 免疫治疗

Abstract: Exosomal PD-L1(exoPD-L1) is secreted by cancer cells in some patients with non-small cell lung cancer and this molecule participates in the development of tumors. As liquid biopsy detection, the detection of exosomal PD-L1 has a great deal of advantages, such as non-invasive and stable. Furthermore, exosomal PD-L1 has a bright prospect in early diagnosis in lung cancer, which also has close contact with TNM of non-small cell lung cancer. Exosomal PD-L1 is related to tumor tissue PD-L1 and can be used to select people who in deed suit immumunotherapy.Monitoring exosomal PD-L1 dynamically is meaningful for evaluating the effects of immunotherapy in patients with non-small cell lung cancer. Study has found that blocking the secretion of exosomal PD-L1 could assist immunotherapy. The application of exosomal PD-L1 is quite potential to the treatment of patients at advanced stage of non-small cell lung cancer.

Key words: non-small cell lung cancer, exosome, PD-L1, diagnosis, immunotherapy

中图分类号:

R734.2

颜晨红, 金儿. 外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展[J]. 基础医学与临床, 2023, 43(9): 1457-1461.

YAN Chenhong, JIN Er. Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer[J]. Basic & Clinical Medicine, 2023, 43(9): 1457-1461.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.09.1457

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I9/1457

参考文献

[1]Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52: 103-109.
[2]Ma Y, Marinkova R, Nenkov M, et al. Tumor-intrinsic PD-L1 exerts an oncogenic function through the activation of the Wnt/β-catenin pathway in human non-small cell lung cancer[J]. Int J Mol Sci, 2022, 23:11031. doi: 10.3390/ijms231911031.
[3]Zhang J, Zhu Y, Guan M, et al. Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response[J]. Nanoscale, 2022, 14:8995-9003.
[4]Yoh KE, Lowe CJ, Mahajan S, et al. Enrichment of circulating tumor-derived extracellular vesicles from human plasma[J]. J Immunol Methods, 2021;490:1129363. doi:10.1016/j.jim.2020.112936.
[5]杨旭东,于红亮,李静,等.巨噬细胞J774A.1外泌体促进结直肠癌细胞系MC38和CT26的增殖和迁移[J]. 基础医学与临床, 2021, 41:799-804.
[6]彭晓潇,刘思思,宋丹妮,等.非小细胞肺癌血浆外泌体PD-L1检测的可行性研究[J]. 循证医学, 2019, 19:119-123.
[7]Zhang W, Zhong W, Wang B, et al. ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression[J].Dev Cell, 2022, 57:329-343.
[8]Ji C, Yang S, Feng M, et al. PD-L1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8⁺ T cell exhaustion during metastasis[J]. Cancer Sci, 2021,112: 3437-3454.
[9]Kim DH, Kim H, Choi YJ, et al. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer[J]. Exp Mol Med, 2019,51: 1-13.
[10]Wu Y, Zeng X, Gan Q. A compact surface plasmon resonance biosensor for sensitive detection of exosomal proteins for cancer diagnosis[J].Methods Mol Biol, 2022, 2393:3-14.
[11]Yang Y, Kannisto E, Yu G, et al. An immuno-biochip selectively captures tumor-derived exosomes and detects exosomal RNAs for cancer diagnosis[J]. ACS Appl Mater Interfaces, 2018, 10:43375-43386.
[12]Sha L, Bo B, Yang F, et al. Programmable DNA-fueled electrochemical analysis of lung cancer exosomes[J]. Anal Chem, 2022, 94:8748-8755.
[13]Li C, Li C, Zhi C, et al. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients[J]. J Transl Med, 2019, 17:355. doi: 10.1186/s12967-019-2101-2.
[14]Zhang Z, Jin W, Xu K, et al. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer[J], Tissue Cell, 2022, 79:101941. doi:10.1016/j.tice.2022.101941.
[15]Shimada Y, Matsubayashi J, Kudo Y, et al. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer[J]. Sci Rep, 2021, 11: 7830. doi:10.1038/s41598-021-87575-3.
[16]Yu S, Shi M, Feng J. Expression of PD-L1 in plasma exosomes of NSCLC patients and its associations with PD-L1 expression of corresponding tumour tissues[J]. Ann Oncol, 2019, 30:v43. doi:10.1093/annonc/mdz239.
[17]Wu F, Gu Y, Kang B, et al. PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer[J]. Transl Lung Cancer Res, 2021, 10:2441-2451.
[18]Yue C, Jiang Y, Li P, et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy[J]. Oncoimmunology, 2018, 7:e1438111. doi:10.1080/2162402X.2018.1438111.
[19]Wang Y, Niu X, Cheng Y, et al. Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients[J].Clin Exp Immunol, 2022, 208:316-322.
[20]Zhang C, Fan Y, Che X, et al. Anti-PD-1 therapy response predicted by the combination of exosomal PD-L1 and CD28[J].Front Oncol, 2020, 10:760. doi:10.3389/fonc.2020.00760.
[21]De Miguel-Perez D, Russo A, Arrieta O, et al. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer[J].J Exp Clin Cancer Res, 2022, 41:186. doi:10.1186/s13046-022-02379-1.
[22]Del Re M, Marconcini R, Pasquini G, et al. PD-L1 mRNA expression in plasma-derived exosomes is associ-ated with response to anti-PD-1 antibodies in melanoma and NSCLC[J]. Br J Cancer, 2018, 118: 820-824.
[23]Cordonnier M, Nardin C, Chanteloup G, et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients[J]. J Extracell Vesicles, 2020, 9:1710899. doi:10.1080/20013078.2019.1710899.
[24]Yang Q, Chen M, Gu J, et al. Novel biomarkers of bynamic blood PD-L1 expression for immune checkpoint inhibitors in advanced non-small-cell lung cancer patients[J]. Front Immunol, 2021, 12:665133.doi:10.3389/fimmu.2021.665133.
[25]Hong W, Xue M, Jiang J, et al. Circular RNA circ-CPA4/let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC)[J]. J Exp Clin Cancer Res, 2020, 39:149. doi:10.1186/s13046-020-01648-1.
[26]Lee CH, Bae JH, Choe EJ, et al. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1[J]. Theranostics, 2022, 12:1971-1987.
[27]Yin Z, Yu M, Ma T, et al. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1[J]. J Immunother Cancer, 2021, 9:e001698. doi:10.1136/jitc-2020-001698.
[28]Xie L, Li J, Wang G, et al. Phototheranostic metal-phenolic networks with antiexosomal PD-L1 enhanced ferroptosis for synergistic immunotherapy[J].J Am Chem Soc, 2022, 144:787-797.

外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展

Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	依马木买买提江·阿布拉, 帕哈尔丁·白克热, 易超, 佟庆. 血浆hsa_circ_005230在原发性肝细胞癌诊断和预后评估中的临床价值[J]. 基础医学与临床, 2023, 43(9): 1417-1422.
[2]	方路, 刘睿奇, 梁鹏, 岑瑛. 外泌体miRNAs在器官纤维化中作用的研究进展[J]. 基础医学与临床, 2023, 43(9): 1472-1476.
[3]	代娣, 刘玉琴. 原发性胃淋巴瘤的诊断难点及治疗进展[J]. 基础医学与临床, 2023, 43(9): 1462-1466.
[4]	杨雅倩, 潘艳芳, 屈梦扬, 方艳, 应小平, 张玫倩, 魏静. 外泌体在肝癌前病变发生发展中作用的研究进展[J]. 基础医学与临床, 2023, 43(9): 1453-1456.
[5]	陈星星, 赛依帕, 胡筱霞, 王三萍, 罗璇, 刘璟. 人脐带间充质干细胞来源外泌体对脑瘫小鼠神经功能损伤的保护作用[J]. 基础医学与临床, 2023, 43(8): 1201-1207.
[6]	张小婉, 康霞, 姚小英, 谢芳, 李莹. 沉默SF3B1促进人肺癌细胞系A549凋亡并抑制其增殖及侵袭[J]. 基础医学与临床, 2023, 43(8): 1265-1270.
[7]	伍琦, 王绍波. CRISPR/Cas9技术在CAR-T细胞治疗肿瘤中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1313-1316.
[8]	陈忠婕, 黄嘉如, 胡清, 赵珍琴, 陈俏俏, 孙浚源, 贾静. 免疫检查点CD276蛋白参与肿瘤发生发展作用机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1143-1147.
[9]	闫霖, 陆珏秀, 罗颖, 刘先霞. BM-MSCs来源外泌体介导铁死亡减轻大鼠心肌细胞系H9c2缺氧/复氧损伤[J]. 基础医学与临床, 2023, 43(5): 771-776.
[10]	李珍, 段昭君, 罗云萍. 神经节苷脂GD2可作为肺癌干细胞一个潜在的候选标志物[J]. 基础医学与临床, 2023, 43(5): 777-784.
[11]	崔诗雨, 张海峰. 外泌体在新型冠状病毒感染和传播中作用的研究进展[J]. 基础医学与临床, 2023, 43(4): 680-684.
[12]	姚刘旭, 李玉红, 蒋宗明. 外泌体lncRNA在结直肠癌液体活检中的研究进展[J]. 基础医学与临床, 2023, 43(2): 317-321.
[13]	姜俣, 钱海燕. 间充质干细胞治疗心肌梗死的研究进展[J]. 基础医学与临床, 2023, 43(1): 21-29.
[14]	商利鹏, 刘国祥, 丁晓燕, 李冰, 赵春华, 李霄霞. 间充质干细胞在衰老相关疾病应用中的研究进展[J]. 基础医学与临床, 2023, 43(1): 38-45.
[15]	陈莉莉, 孙永红, 雷晓燕, 王建军, 陈星星, 鲍柏辛. 间充质干细胞外泌体治疗肺部疾病的研究进展[J]. 基础医学与临床, 2023, 43(1): 192-195.